Provided by Tiger Trade Technology Pte. Ltd.

Cumberland Pharmaceuticals

6.39
-0.0900-1.39%
Post-market: 6.400.0101+0.16%16:51 EDT
Volume:16.65K
Turnover:107.13K
Market Cap:95.57M
PE:-8.64
High:6.75
Open:6.61
Low:6.38
Close:6.48
52wk High:9.28
52wk Low:1.85
Shares:14.96M
Float Shares:8.75M
Volume Ratio:0.69
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7398
EPS(LYR):-0.1909
ROE:-14.39%
ROA:-2.91%
PB:5.48
PE(LYR):-33.47

Loading ...

Cumberland Pharmaceuticals Sets Executive Pay “say-on-Pay” Vote Every Three Years

Reuters
·
Yesterday

Cumberland Pharmaceuticals Updates Ifetroban DMD Trial Timeline

TIPRANKS
·
Aug 29

Cumberland Pharma Says Ifetroban Phase 2 DMD Extension Data not Ready, Pulls August 2026 Timing

Reuters
·
Aug 29

Cumberland Pharmaceuticals Q2 Loss Widens After Apotex Transaction

Reuters
·
Aug 05

Cumberland Pharmaceuticals Q2 Adjusted EPS USD -0.2

THOMSON REUTERS
·
Aug 05

Cumberland Pharmaceuticals Q2 FY26 Net Loss Widens to USD 4.1 Million; Revenue Falls 56.28% to USD 166,458

Reuters
·
Aug 05

Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY

Benzinga Earnings
·
Aug 05

Cumberland Pharmaceuticals Reports Company Update & Q2 2026 Financial Results

THOMSON REUTERS
·
Aug 05

Cumberland Declares Special Dividend, Approves $5 Million Share Buyback

MT Newswires Live
·
Jul 13

Cumberland board authorizes $5M share repurchase program

TIPRANKS
·
Jul 13

Cumberland Pharmaceuticals - Authorizes Open-market Share Repurchase Program of up to $5 Mln

THOMSON REUTERS
·
Jul 13

Cumberland Pharmaceuticals Announces Special Dividend of $1.50 Per Share

THOMSON REUTERS
·
Jul 13

Press Release: Cumberland Pharmaceuticals Announces Special Dividend of $1.50 PER SHARE

Dow Jones
·
Jul 13

Cumberland Pharmaceuticals Closes USD 100 Million Branded-drug Sale to Apotex Unit

Reuters
·
Jul 01

Press Release: Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals

Dow Jones
·
Jul 01

Cumberland Pharma Updates Phase 2 FIGHT DMD Trial Data Showing 5.4% LVEF Gain with Ifetroban in Duchenne Cardiomyopathy

Reuters
·
Jun 26

Cumberland Pharmaceuticals Shareholders Approve Apotex-linked Asset Sale Proposal at Special Meeting

Reuters
·
Jun 26

RedHill Biopharma posts corporate presentation on Talicia commercialization and GI-focused pipeline

Reuters
·
Jun 15

Cumberland announces data from Phase 2a clinical trial of ifetroban

TIPRANKS
·
Jun 02

Cumberland Pharmaceuticals, Vanderbilt Health Report Positive Phase 2a Results for Ifetroban in Metastasis Prevention Study

MT Newswires Live
·
Jun 02